Potential drug–drug interactions in medical intensive care unit of a tertiary care hospital in Pakistan

International Journal of Clinical Pharmacy

Volumn 38, Issue 5, 2016, Pages 1052-1056

  Ismail, Mohammad ^a   Khan, Farmanullah ^a   Noor, Sidra ^a   Haider, Iqbal ^b   Haq, Inam ul ^a   Ali, Zahid ^a   Shah, Zahir ^a   Hassam, Mohsin ^a  

^a UNIVERSITY OF PESHAWAR   (Pakistan)

^b KHYBER TEACHING HOSPITAL   (Pakistan)

Author keywords

Adverse drug event; Clinical pharmacy; Drug interaction; Drug related problem; Intensive care unit; Pakistan Potential drug drug interaction

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; CALCIUM; CARBAMAZEPINE; CEFTRIAXONE; CLARITHROMYCIN; CLOPIDOGREL; DEXAMETHASONE; DIAZEPAM; FUROSEMIDE; INSULIN; ISONIAZID; METRONIDAZOLE; OMEPRAZOLE; PYRAZINAMIDE; RIFAMPICIN; SALBUTAMOL; SODIUM DIHYDROGEN PHOSPHATE;

ADVERSE DRUG REACTION; ARTICLE; DISEASE SEVERITY; DRUG INTERACTION; EVIDENCE BASED MEDICINE; FEMALE; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; PAKISTAN; PATIENT MONITORING; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; TERTIARY CARE CENTER; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; DRUG MONITORING; EPIDEMIOLOGY; HOSPITALIZATION; PHYSIOLOGY; RISK FACTOR; TRENDS;

DRUG INTERACTIONS; DRUG MONITORING; FEMALE; HOSPITALIZATION; HUMANS; INTENSIVE CARE UNITS; MALE; PAKISTAN; RISK FACTORS; TERTIARY CARE CENTERS;

EID: 84976497518     PISSN: 22107703     EISSN: 22107711     Source Type: Journal    
DOI: 10.1007/s11096-016-0340-3     Document Type: Article

References (11)

1. Uijtendaal EV, van Harssel LL, Hugenholtz GW, Kuck EM, Zwart-van Rijkom JE, Cremer OL, et al. Analysis of potential drug–drug interactions in medical intensive care unit patients. Pharmacotherapy. 2014;34:213–9.
2. Reis AM, Cassiani SH. Prevalence of potential drug interactions in patients in an intensive care unit of a university hospital in Brazil. Clinics (Sao Paulo). 2011;66:9–15.
3. Rodrigues AT, Stahlschmidt R, Granja S, Falcão ALE, Moriel P, Mazzola PG. Clinical relevancy and risks of potential drug–drug interactions in intensive therapy. Saudi Pharm J. 2015;23:366–70.
4. Abideen S, Vivekanandan K, Mishra P. Assessment of prevalence of potential drug–drug interactions in medical intensive care unit of a tertiary care hospital in India. Asian J Pharm Clin Res. 2015;8:125–30.
5. Ismail M, Iqbal Z, Khattak MB, Khan MI, Arsalan H, Javaid A, et al. Potential drug–drug interactions in internal medicine wards in hospital setting in Pakistan. Int J Clin Pharm. 2013;35:455–62.
6. ®. Greenwood Village, CO: Truven Health Analytics, USA. http://www.micromedexsolutions.com/home/dispatch. Accessed 17 Feb 2016.
7. Egger SS, Drewe J, Schlienger RG. Potential drug–drug interactions in the medication of medical patients at hospital discharge. Eur J Clin Pharmacol. 2003;58:773–8.
8. van Leeuwen RWF, Swart EL, Boven E, Boom FA, Schuitenmaker MG, Hugtenburg JG. Potential drug interactions in cancer therapy: a prevalence study using an advanced screening method. Ann Oncol. 2011;22:2334–41.
9. Ismail M, Iqbal Z, Khattak MB, Javaid A, Khan MI, Khan TM, et al. Potential drug–drug interactions in psychiatric ward of a tertiary care hospital: prevalence, levels and association with risk factors. Trop J Pharm Res. 2012;11:289–96.
10. Ismail M, Iqbal Z, Khan MI, Javaid A, Arsalan H, Farhadullah, et al. Frequency, levels and predictors of potential drug–drug interactions in a pediatrics ward of a teaching hospital in Pakistan. Trop J Pharm Res. 2013;12:401–6.
11. Roblek T, Vaupotic T, Mrhar A, Lainscak M. Drug–drug interaction software in clinical practice: a systematic review. Eur J Clin Pharmacol. 2015;71:131–42.